These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8165852)

  • 41. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine.
    Eskola J; Olander RM; Hovi T; Litmanen L; Peltola S; Käyhty H
    Lancet; 1996 Dec 21-28; 348(9043):1688-92. PubMed ID: 8973430
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period.
    Miller MA; Meschievitz CK; Ballanco GA; Daum RS
    Pediatrics; 1995 Apr; 95(4):522-7. PubMed ID: 7700752
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines.
    Rennels MB; Reed GF; Decker MD; Edwards KM; Pichichero ME; Deloria MA; Englund JA; Anderson EL; Steinhoff MC; Deforest A
    Pediatrics; 1995 Sep; 96(3 Pt 2):576-9. PubMed ID: 7659479
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants.
    Anderson EL; Belshe RB; Bartram J
    J Infect Dis; 1988 Apr; 157(4):731-7. PubMed ID: 2894399
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens.
    Miller E; Ashworth LA; Robinson A; Waight PA; Irons LI
    Lancet; 1991 Jan; 337(8733):70-3. PubMed ID: 1670725
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity, reactogenicity and safety of three-dose primary and booster vaccination with combined diphtheria-tetanus-whole-cell pertussis-hepatitis B-reduced antigen content Haemophilus influenzae type b vaccine in Filipino children.
    Gatchalian SR; Ramakrishnan G; Bock HL; Lefevre I; Jacquet JM
    Hum Vaccin; 2010 Aug; 6(8):664-72. PubMed ID: 20657177
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children.
    Morgan CM; Blumberg DA; Cherry JD; Reisinger KS; Blatter MM; Blumer JL; Dekker CL; Stout MG; Christenson PD
    Am J Dis Child; 1990 Jan; 144(1):41-5. PubMed ID: 2403747
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study.
    Englund JA; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Anderson EL
    Pediatrics; 1994 Jan; 93(1):37-43. PubMed ID: 8265321
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine.
    Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; uberall M; Laussucq S; Eckhardt T; Meyer M; Engelhardt R; Christenson P
    Pediatrics; 1998 Jan; 101(1 Pt 1):1-11. PubMed ID: 9417143
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity and reactogenicity of the component acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous haemagglutinin.
    Kimura M; Kuno-Sakai H; Kamiya H; Ueda K; Isomura S; Koike M; Kato T; Ozaki T; Hirose M; Egami T
    Acta Paediatr Jpn; 1995 Oct; 37(5):562-74. PubMed ID: 8533580
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age.
    Huang LM; Lee CY; Lin TY; Chen JM; Lee PI; Hsu CY
    Vaccine; 1996 Jun; 14(9):916-22. PubMed ID: 8843635
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and immunogenicity of an acellular pertussis vaccine booster in 15- to 20-month-old children previously immunized with acellular or whole-cell pertussis vaccine as infants.
    Pichichero ME; Francis AB; Marsocci SM; Green JL; Disney FA; Meschievitz C
    Pediatrics; 1993 Apr; 91(4):756-60. PubMed ID: 8464662
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The multicenter acellular pertussis trial: an overview.
    Decker MD; Edwards KM
    J Infect Dis; 1996 Nov; 174 Suppl 3():S270-5. PubMed ID: 8896528
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines.
    Steinhoff MC; Reed GF; Decker MD; Edwards KM; Englund JA; Pichichero ME; Rennels MB; Anderson EL; Deloria MA; Meade BD
    Pediatrics; 1995 Sep; 96(3 Pt 2):567-70. PubMed ID: 7659477
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV).
    Knuf M; Vetter V; Celzo F; Ramakrishnan G; Van Der Meeren O; Jacquet JM
    Hum Vaccin; 2010 Jul; 6(7):554-61. PubMed ID: 20448468
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines.
    Boros CA; Hanlon M; Gold MS; Roberton DM
    Vaccine; 2001 May; 19(25-26):3537-42. PubMed ID: 11348721
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody.
    Blumberg DA; Mink CM; Cherry JD; Reisinger KS; Blatter MM; Congeni BL; Dekker CL; Stout MG; Mezzatesta JR; Scott JV
    J Pediatr; 1990 Jul; 117(1 Pt 1):46-51. PubMed ID: 2196360
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Japanese clinical trials with Takeda acellular pertussis vaccine.
    Kuno-Sakai H; Kimura M; Ozaki K; Isomura S; Kamiya H; Nii R; Kato T; Horiuchi K; Syukuda Y; Fujita I
    Tokai J Exp Clin Med; 1988; 13 Suppl():15-9. PubMed ID: 2908519
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis.
    Giuliano M; Mastrantonio P; Giammanco A; Piscitelli A; Salmaso S; Wassilak SG
    J Pediatr; 1998 Jun; 132(6):983-8. PubMed ID: 9627590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.